What is HC Wainwright’s Forecast for DMRA Q3 Earnings?

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) – Equities researchers at HC Wainwright dropped their Q3 2026 earnings estimates for Damora Therapeutics, Inc. Common Stock in a note issued to investors on Tuesday, August 11th. HC Wainwright analyst M. Kapoor now anticipates that the company will post earnings of ($0.37) per share for the quarter, down from their previous forecast of ($0.33). HC Wainwright currently has a “Buy” rating and a $45.00 target price on the stock. The consensus estimate for Damora Therapeutics, Inc. Common Stock’s current full-year earnings is ($1.92) per share. HC Wainwright also issued estimates for Damora Therapeutics, Inc. Common Stock’s Q4 2026 earnings at ($0.38) EPS, FY2026 earnings at ($1.67) EPS, Q1 2027 earnings at ($0.38) EPS, Q2 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.41) EPS and FY2027 earnings at ($1.59) EPS.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.39) EPS for the quarter, topping the consensus estimate of ($0.45) by $0.06.

Several other equities analysts have also recently weighed in on DMRA. Royal Bank Of Canada assumed coverage on Damora Therapeutics, Inc. Common Stock in a research report on Friday, April 24th. They issued an “outperform” rating and a $40.00 price target for the company. Jefferies Financial Group initiated coverage on Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They issued a “buy” rating and a $50.00 target price for the company. Wedbush lifted their target price on Damora Therapeutics, Inc. Common Stock from $35.00 to $40.00 and gave the company an “outperform” rating in a report on Thursday, July 30th. TD Cowen started coverage on Damora Therapeutics, Inc. Common Stock in a research report on Monday, June 8th. They set a “buy” rating on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Thursday, June 18th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $44.00.

Damora Therapeutics, Inc. Common Stock Price Performance

Shares of DMRA stock opened at $31.00 on Thursday. The stock has a market capitalization of $1.91 billion, a price-to-earnings ratio of -5.56 and a beta of 1.47. The company’s fifty day simple moving average is $26.88 and its two-hundred day simple moving average is $26.32. Damora Therapeutics, Inc. Common Stock has a 1 year low of $2.45 and a 1 year high of $38.33.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

Several institutional investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC bought a new stake in Damora Therapeutics, Inc. Common Stock in the 4th quarter worth $40,000. Virtu Financial LLC bought a new position in shares of Damora Therapeutics, Inc. Common Stock during the third quarter valued at about $49,000. Two Sigma Investments LP purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock during the third quarter worth about $76,000. Connective Capital Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the third quarter worth about $100,000. Finally, Geode Capital Management LLC bought a new stake in shares of Damora Therapeutics, Inc. Common Stock in the fourth quarter worth about $266,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.